Navigation Links
Improve Recovery and Reproducibility with Pre-Treatment of Analytical TSK-GEL G3000SWXL Size Exclusion Columns

T.J. Higley, Tosoh Bioscience LLC and Richard Cornell, Wyeth BioPharma


Abstract:
During a recent method optimization and investigation at Wyeth BioPharma, pre-treatment with bovine serum albumin improved reproducibility and recovery during the analytical SEC analysis of fractions pulled from a multi-step orthogonal purification of a 140 kDa apparent molecular weight protein from cell culture feedstock.


Introduction:
Ideally in size exclusion chromatography the only mechanism that provides separation of sample components is a sieving process based on the hydrodynamic radius of the sample components in combination with a porous and non-interactive stationary phase. For monodispersed samples such as proteins, spherical 5 micron silica-based materials derivatized with proprietary hydrophilic diol-type coatings have been widely used since their introduction by Kato et al. in 1987. Although exhaustively derivatized, unreacted silanol groups and the hydrophilic coating may contribute to unwanted ionic or hydrophobic interactions between the bonded phase and sample components. One technique to reduce the impact of such secondary interactions is to inject bovine serum albumin to occupy accessible reactive sites on the stationary phase.

At Wyeth BioPharma, a SEC analysis is employed at every stage of a three step cell culture purification to determine the purity and recovery of the high molecular weight species of the target protein. The cell culture is purified using affinity chromatography (protein A) and subsequent chromatographic polishing steps. The recovery and reproducibility of the peaks eluting in the region of high mole cular weight species during SEC analysis of the post-protein A fraction was highly variable, signaling possible adsorption of the sample to the packing materials. A pre-treatment experimental protocol with BSA was administered to reduce the variability.


Conditions of SEC analysis:
Column: TSKgel G3000SWXL, 30cm x 7.8mm, 5 micron

Elution: Phosphate Buffered Saline, pH 6.5

Sample: 50 mL injection volume, 50 mg load

Detection: 280 nm

Instrument: Waters 2690 Alliance


Results:
As can be seen in Figure 1 , recovery of the high molecular weight region, expressed as a percent of total area recovery (% HMW), of the protein A purified sample was 1.1%. Upon injecting 10 aliquots x 20 mL of 5 mg/mL bovine serum albumin (BSA) onto the column, the recovery of the %HMW species increased to 3.5%. In the absence of BSA treatment, protein A purified samples historically returned %HMW values of 1.0% to 1.4% when a column was new and gradually increased to 3.5% - 4.0% after as many as 60 injections. Interestingly, this result was only apparent with the protein A purified sample. Table 1 shows that BSA pre-treatment had no effect on the samples obtained from the downstream chromatography steps. Further characterization work indicated that elevated levels of host cell proteins (HCP) were present in the protein A purified samples with respect to the post polishing samples. The HCP were found to elute in the HMW region of the analytical SEC profile. Furthermore, when the protein A purified samp les were analyzed by analytical SEC after BSA treatment, the HMW region was found to be enriched in host cell protein when compared to the HMW region of the same sample run on analytical SEC prior to BSA treatment. This suggests that the association between sample and column packing was most prevalent with the HCP as opposed to target molecule HMW species.




Conclusions:
Pre-treatment of SEC columns with BSA is a viable option to reduce secondary interactions and improve consistency of results between analyses. In this particular protocol, the dramatic improvement in the Improve Recovery and Reproducibility with Pre-Treatment of Analytical TSK-GEL G3000SWXL Size Exclusion Columns T.J. Higley, Tosoh Bioscience LLC and Richard Cornell, Wyeth BioPharma Figure 1. Overlay plot of the Protein A sample pre and post-treatment with BSA Sample % HMW pre treatment % HMW post treatment Post Protein A 1.1 3.4 Post Polishing chromatographic step1 1.5 1.5 Post Polishing chromatographic step 2 (final product) 0.2 0.2 Table 1: Recoveries of all three types of samples pre and post-treatment with BSA consistency of results associated with the protein A purified fraction, in contrast to the lack of effect seen on recovery of HMW species from downstream purification steps (chromatographic polishing steps 1 and 2), has provided the opportunity to further characterize the high molecular weight fractions of the protein A purified sample. This characterization has led to the conclusion that the results of SEC performed on samples from early purification steps may be negatively influenced by non-product related impurities derived from the cell c ulture environment.


References:
Y. Kato et al; J. of Chromatrogr. 404 (1987) 333-339


More Infomation
TSKgel G3000SWxl



'"/>

Source:


Page: All 1 2 3 4

Related biology technology :

1. The Best Enzyme for the Toughest PCR Challenges Improved with New Hot-Start Feature
2. Novel PCR Enhancing Factor Improves Performance of Pfu DNA Polymerase
3. Improved Sensitivity for Staining RNA with SYBR Gold Stain
4. Improve Lipid- or Calcium Phosphate-Mediated Transfection of Human Dermal Fibroblasts
5. Improved Vectors for PathDetect Trans-Reporting Systems
6. Improve Amplification Specificity with Hot Start PCR Enzyme
7. Improved Quantitative Selectivity of Clenbuterol in Human Urine using High Resolution on the TSQ Quantum Mass Spectrometer
8. Gene Expression Arrays: Highly Sensitive Detection of Expression Patterns with Improved Tools for Target Amplification
9. Improve RNA Isolation for Array Analysis and More
10. Protect RNA and Improve Target Cell Identification
11. The Worlds Best DNase Improved TURBO DNA-free
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/9/2016)... ... February 09, 2016 , ... ... innovations on its free and validated Electronic Data Capture (EDC) system ClinCaptureand its ... in Clinical Trials West Coast 2016 Conference in San Mateo, California on February ...
(Date:2/9/2016)... HOUSTON , Feb. 9, 2016 /PRNewswire/ ... virus-driven immunotherapies for cancer, announced that its ... the European Commission as an orphan medicinal ... the deadliest form of glioma, strikes approximately ... and EU. http://photos.prnewswire.com/prnh/20160208/330986LOGO ...
(Date:2/9/2016)... 9, 2016 DelveInsight,s, ... report provides in depth insights on the ... the Protein-Tyrosine Phosphatase 1B (PTP1B) Inhibitors. The ... various stages of development including Discovery, Pre-clinical, ... and Preregistration. Report covers the product clinical ...
(Date:2/8/2016)... Inc. today announced that Director Robert A. Ingram has ... addition, Robert Keegan has been appointed to the Board ... --> North Carolina . --> ... $32.8 million of net proceeds in a private Mezzanine B financing ... Research Triangle area of North Carolina . ...
Breaking Biology Technology:
(Date:1/15/2016)... Rico , Jan. 15, 2016 Recent ... and small to find new ways to ensure data ... iOS and Android that ... on biometrics, transforming it into a hardware authorization token. ... users swipe their fingerprint on their KodeKey enabled device ...
(Date:1/11/2016)... Calif. , Jan. 11, 2016 Synaptics ... human interface solutions, today announced that its ClearPad ® ... integration (TDDI) products won two separate categories in the ... Mobile Innovator and Best Technology Breakthrough. The Synaptics ® ... cost, a simplified supply chain, thinner devices, brighter displays ...
(Date:1/8/2016)... 8, 2016 NXTD ), a ... ® , a privately held leading direct seller of ... 5000 fastest-growing company announced that on December 31, ... million in Nxt-ID to develop a proprietary new wireless ... ® , a unique smart wallet that serves to ...
Breaking Biology News(10 mins):